Optimal Dosing of the Poly(ADP-Ribose) Polymerase Inhibitor Niraparib

May 29-31, 2020; Online at meetings.asco.org/am
Individualized dosing of niraparib based on weight and platelet count improves tolerability with no loss of efficacy.
Format: Microsoft PowerPoint (.ppt)
File Size: 212 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
GlaxoSmithKline
Merck Sharp & Dohme Corp.
Novartis Pharmaceuticals Corporation

Related Content

Expert commentary on the use of PARP inhibitors as frontline maintenance therapy in the treatment of ovarian cancer, from Clinical Care Options

Ursula Matulonis, MD Released: January 11, 2021

In this slideset, CCO’s expert faculty explores the role of biomarkers and HRD when treating patients with ovarian cancer using PARP inhibitors

person default Alexandra Leary, MD, PhD Released: December 22, 2020

CCO’s expert faculty reviews PARP inhibitors in the treatment of patients with recurrent ovarian cancer.

Ursula Matulonis, MD Released: December 22, 2020

CCO’s expert faculty reviews the different PARP inhibitors in the treatment of patients with newly diagnosed ovarian cancer.

Prof Ignace Vergote Released: December 22, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue